Literature DB >> 16741521

Use of the PSA enhancer core element to modulate the expression of prostate- and non-prostate-specific basal promoters in a lentiviral vector context.

S Chapel-Fernandes1, F Jordier, F Lauro, N Maitland, J Chiaroni, P de Micco, P Mannoni, C Bagnis.   

Abstract

Composite promoters combining the prostate-specific antigen (PSA) enhancer core element with promoter elements derived from gene coding for human prostate-specific transglutaminase gene, prostate-specific membrane antigen gene, prostate-specific antigen, rat probasin or phosphoglycerate kinase were characterized for their ability to specifically express the enhanced green fluorescent protein (EGFP) gene in prostate versus non-prostate cancer cell lines when transferred with a human immunodeficiency virus-1-based lentiviral vector. By themselves minimal proximal promoter elements were found to inefficiently promote relevant tissue-specific expression; in all the vectors tested, addition of the PSA enhancer core element markedly improved EGFP expression in LnCaP, a cancer prostate cell line used as a model for prostate cancer. The composite promoter was inactive in HuH7, a hepatocarcinoma cell line used as a model of neighboring non-prostate cancer cells. Among the promoters tested, the combination of the PSA enhancer and the rat probasin promoter showed both high specificity and a strong EGFP expression. Neither a high viral input nor the presence of the cPPT/CTS sequence affected composite promoter behavior. Our data suggest that composite prostate-specific promoters constructed by combining key elements from various promoters can improve and/or confer tissue specific expression in a lentiviral vector context.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16741521     DOI: 10.1038/sj.cgt.7700966

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  2 in total

1.  Simian virus 40 enhancer does not affect the tumor specificity of human heparanase gene promoter.

Authors:  Bin Chen; Xiao-Peng Chen; Yong Wang; Wei Cui; Min Zhong
Journal:  Biomed Rep       Date:  2012-06-07

2.  Overcoming mutation-based resistance to antiandrogens with rational drug design.

Authors:  Minna D Balbas; Michael J Evans; David J Hosfield; John Wongvipat; Vivek K Arora; Philip A Watson; Yu Chen; Geoffrey L Greene; Yang Shen; Charles L Sawyers
Journal:  Elife       Date:  2013-04-09       Impact factor: 8.140

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.